Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Recruiting now

Conditions studied: Oral Neoplasm

In brief

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Key facts

Study ID

NCT04622462

Run by

Proteocyte Diagnostics Inc.

People needed

500

Starts

2015-03-12

Expected to finish

2026-12-31

Last updated by the study team

2024-11-07

Who can join

Age: 15 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma

You may not qualify if…

• Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy

Where it is running

• Kingsway Oral & Maxillofacial Surgery — Edmonton, Alberta, Canada (enrolling)
• University of Alberta — Edmonton, Alberta, Canada (enrolling)
• Western University — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.